J&J boosts medtech biz with $13.1B Shockwave deal
2024-04-05
并购
Johnson & Johnson will acquire all outstanding shares of cardiovascular medical device company Shockwave Medical, in a deal valued at approximately $13.1 billion.
California-based Shockwave provides innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD). The tech is a minimally invasive, catheter-based treatment for calcified arterial lesions, which can reduce blood flow and lead to pain or heart attacks.
For J&J, the deal beefs up its medtech unit's position in cardiovascular intervention and speeds up its shift into higher-growth markets. The acquisition will expand J&J MedTech's cardiovascular portfolio into two growing segments of cardiovascular intervention — CAD and PAD.
The transaction follows J&J MedTech’s $16.6 billion acquisition of heart pump maker Abiomed in December 2022 and a $400 million buy of heart device maker Laminar in November 2023.
More recently, J&J inked a deal to acquire San Diego-based Ambrx Biopharma in a next-gen ADC deal valued at approximately $2 billion.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。